Investigator

Esmeralda Capristo

Professore Associato · Università Cattolica del Sacro Cuore, Dipartimento di Scienze Mediche e Chirurgiche Addominali ed Endocrino Metaboliche

About

ECEsmeralda Capristo
Papers(1)
Clinical Tolerability…
Collaborators(9)
Giuditta ChiloiroMarco CintoniMaria Antonietta Gamb…Maria Cristina MelePauline Celine RaoulRaffaella Michela Rin…Rosa AutorinoAntonio GasbarriniEmanuele Rinninella
Institutions(2)
Universit Cattolica D…Policlinico Universit…

Papers

Clinical Tolerability and Safety of Ketogenic Diet in Patients with Gynecological Malignancies Undergoing Radiotherapy: Preliminary Results of a Prospective, Randomized, Open-Label Trial (KOMPARC)

Background: Radiotherapy is a common treatment for gynecological malignancies, often accompanied by significant side effects that impact patient nutritional status. The ketogenic diet has been proposed as a complementary nutritional strategy to enhance treatment efficacy, manage side effects, and preserve body composition. However, its safety and feasibility in the oncological setting remain under-investigated. Methods: The KOMPARC study is a prospective, randomized controlled trial evaluating the adherence, safety, and clinical tolerability of a ketogenic diet versus a standard Mediterranean diet in patients with cervical and endometrial cancer undergoing radiotherapy. Before the start of the treatment, patients were randomized to either the ketogenic diet or the standard diet groups. Anthropometric measures, Hand Grip Test, and body composition parameters from bioimpedance analysis were taken before the start of treatment and at the end. Adherence, adverse events, and patient-reported outcomes were monitored throughout the treatment period. Results: A total of 33 patients were enrolled. Adherence rates were comparable between the KD and standard diet groups (46.1% vs. 25.0% interruption rate, p = 0.21). No significant differences were observed in the incidence of gastrointestinal toxicities (p = 0.56), diarrhea (p = 0.81), nausea (p = 0.94), or weight loss (p = 0.24). Both groups experienced significant weight reduction during therapy without differential loss of body cell mass or other body composition parameters. Quality of life assessments indicated varied symptom profiles, with the KD group reporting increased appetite loss and worry about weight. Conclusions: Preliminary findings suggest that the ketogenic diet is a safe and feasible nutritional intervention during radiotherapy for pelvic tumors. These results support further investigation into ketogenic dietary strategies as adjuncts in oncologic care.

160Works
1Papers
9Collaborators

Positions

Professore Associato

Università Cattolica del Sacro Cuore · Dipartimento di Scienze Mediche e Chirurgiche Addominali ed Endocrino Metaboliche

2002–

Dirigente Medico

Policlinico Universitario Agostino Gemelli Dipartimento di scienze mediche e chirurgiche · Dipartimento di Scienze Mediche e Chirurgiche Addominali ed Endocrino Metaboliche

Country

IT

Keywords
Obesity
Links & IDs
0000-0002-5753-3495

Scopus: 7005031634